by 
Calcineurin inhibitors are immunosuppressants that are critically important for managing organ transplant rejection. They work by inhibiting the phosphatase activity of calcineurin, which is required for the activation of T-cells and B-cells during an immune response. The two most commonly prescribed calcineurin inhibitors are cyclosporine and tacrolimus. They are used long-term as maintenance therapy after transplantation of organs like kidney, liver, heart and lungs to prevent graft rejection. The number of organ transplantation procedures has significantly risen in recent years owing to rising prevalence of organ failure diseases and growing awareness about organ donation. According to the United Network for Organ Sharing, there were over 40,000 organ transplants performed in the United States in 2021 alone. The global Calcineurin Inhibitor Market is estimated to be valued at US$ 10.07 Bn in 2024 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: One of the key trends in the calcineurin inhibitor market is the development of novel drug delivery formulations. Both cyclosporine and tacrolimus currently available are associated with side effects due to non-specific tissue distribution and erratic absorption from the gastrointestinal tract. There is an ongoing research focus on developing improved formulations that can deliver the drug specifically to target organs and tissues, while avoiding systemic exposure. This can help reduce toxicity and improve treatment compliance. Another trend is the development of calcineurin inhibitor alternatives such as belatacept and voclosporin that are less nephrotoxic. These novel molecules offer efficacy comparable to cyclosporine without accompanying kidney damage. Their approvals are likely to help address the unmet needs and expand the market size over the forecast period.
Porter’s Analysis
Threat of new entrants: The Calcineurin Inhibitor Market has moderate threat of new entrants given the established presence of key players in the market. New players will require significant investment in R&D to develop novel calcineurin inhibitor drugs.
Bargaining power of buyers: Buyers have moderate bargaining power owing to the availability of established branded as well as generic versions of calcineurin inhibitors. However, switching costs are low due to easy availability of substitutes.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to availability of a wide range of suppliers providing raw materials for manufacturing calcineurin inhibitors.
Threat of new substitutes: The threat of new substitutes is low as calcineurin inhibitors are effective therapeutic options for immunosuppression. Potential substitutes may require significant clinical testing and commercialization efforts.
Competitive rivalry: The market has high competitive rivalry with key players focusing on new product launches and expansion to emerging markets.
Key Takeaways
The global Calcineurin Inhibitor Market is expected to witness high growth over the forecast period.
Regional analysis: North America dominates the Calcineurin Inhibitor Market owing to increased transplantation procedures, favorable reimbursement policies, and rising prevalence of autoimmune diseases. Asia Pacific region is anticipated to exhibit fastest growth during the forecast period.
Key players operating in the Calcineurin Inhibitor Market are Novartis AG, Amgen, F. Hoffmann-La Roche Ltd, Pfizer Inc., Incyte Corporation, Chiesi Farmaceutici S.p.A., Astellas Pharma Inc., Sanofi SA, Bristol Myers Squibb Company, Mylan N.V., Dr. Reddy’s Laboratories Ltd., Senju Pharmaceutical Co. Ltd, Abbott, Lupin Limited, and Vibcare Pharma Pvt. Ltd.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
